Kurkinen M - Search Results

1

Silent brain infarcts and leukoaraiosis in young adults with first-ever ischemic stroke.

Putaala J, Kurkinen M, Tarvos V, Salonen O, Kaste M, Tatlisumak T. Putaala J, et al. Among authors: kurkinen m. Neurology. 2009 May 26;72(21):1823-9. doi: 10.1212/WNL.0b013e3181a711df. Neurology. 2009. PMID: 19470964

2

Silent brain infarcts, leukoaraiosis, and long-term prognosis in young ischemic stroke patients.

Putaala J, Haapaniemi E, Kurkinen M, Salonen O, Kaste M, Tatlisumak T. Putaala J, et al. Among authors: kurkinen m. Neurology. 2011 May 17;76(20):1742-9. doi: 10.1212/WNL.0b013e31821a44ad. Neurology. 2011. PMID: 21576692

3

Roll-to-roll fabrication of integrated PDMS-paper microfluidics for nucleic acid amplification.

Hiltunen J, Liedert C, Hiltunen M, Huttunen OH, Hiitola-Keinänen J, Aikio S, Harjanne M, Kurkinen M, Hakalahti L, Lee LP. Hiltunen J, et al. Among authors: kurkinen m. Lab Chip. 2018 May 29;18(11):1552-1559. doi: 10.1039/c8lc00269j. Lab Chip. 2018. PMID: 29708259

4

Disposable roll-to-roll hot embossed electrophoresis chip for detection of antibiotic resistance gene mecA in bacteria.

Liedert R, Amundsen LK, Hokkanen A, Mäki M, Aittakorpi A, Pakanen M, Scherer JR, Mathies RA, Kurkinen M, Uusitalo S, Hakalahti L, Nevanen TK, Siitari H, Söderlund H. Liedert R, et al. Among authors: kurkinen m. Lab Chip. 2012 Jan 21;12(2):333-9. doi: 10.1039/c1lc20782b. Epub 2011 Nov 29. Lab Chip. 2012. PMID: 22127494

5

Anti-amyloid treatments in Alzheimer's disease: elegance, evidence and ethics.

Daly T, Olluri A, Kurkinen M. Daly T, et al. Among authors: kurkinen m. Adv Clin Exp Med. 2024 Dec;33(12):1303-1309. doi: 10.17219/acem/198674. Adv Clin Exp Med. 2024. PMID: 39698778 Free article.

6

Survival time in Alzheimer's disease: An overlooked measure of safety and efficacy of disease-modifying therapies.

Kurkinen M, Daly T. Kurkinen M, et al. Adv Clin Exp Med. 2024 Oct;33(10):1039-1043. doi: 10.17219/acem/194003. Adv Clin Exp Med. 2024. PMID: 39412276 Free article. Review.

7

Measuring our language about anti-amyloid antibodies in Alzheimer's disease: Technical, theoretical, and lay language considerations.

Daly T, Kurkinen M. Daly T, et al. Among authors: kurkinen m. Clin Neurol Neurosurg. 2024 Jun;241:108314. doi: 10.1016/j.clineuro.2024.108314. Epub 2024 Apr 30. Clin Neurol Neurosurg. 2024. PMID: 38703469 No abstract available.

8

Anti-amyloid therapies do not slow Alzheimer's disease progression.

Kurkinen M. Kurkinen M. Dement Neuropsychol. 2024 Jan 5;17:e20230099. doi: 10.1590/1980-5764-DN-2023-0099. eCollection 2023. Dement Neuropsychol. 2024. PMID: 38189031 Free PMC article. No abstract available.

9

Donanemab: Not two without a third.

Kurkinen M. Kurkinen M. Adv Clin Exp Med. 2023 Oct;32(10):1085-1087. doi: 10.17219/acem/172673. Adv Clin Exp Med. 2023. PMID: 37831471 Free article.

10

Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.

Kurkinen M. Kurkinen M. Adv Clin Exp Med. 2023 Sep;32(9):943-947. doi: 10.17219/acem/171379. Adv Clin Exp Med. 2023. PMID: 37676096 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters